GlassScriptPhysician profile
James M Sullivan
NPI 1275697161
$6,836.66
in general payments reported to CMS, 2019-2025
25 companies · $463 in 2025
The $463 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,313 · 2020: $714 · 2021: $1,597 · 2022: $1,231 · 2023: $926 · 2024: $591 · 2025: $463.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,921 · Education: $59.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,920.81 |
| Education | $59.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,856.90 | 2019-2025 | Rinvoq, Skyrizi |
| Pfizer INC. | $979.57 | 2019-2025 | |
| Amgen INC. | $960.26 | 2019-2024 | Enbrel, Tavneos, Otezla |
| Ucb, INC. | $399.22 | 2019-2024 | Cimzia, Bimzelx |
| Lilly USA, LLC | $283.62 | 2020-2022 | |
| Mallinckrodt Hospital Products INC. | $231.37 | 2020-2021 | |
| Mallinckrodt Enterprises LLC | $215.76 | 2019 | |
| Janssen Biotech, INC. | $198.14 | 2019-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $148.26 | 2019-2020 | |
| Celgene Corporation | $85.18 | 2019 | |
| Janssen Pharmaceuticals, INC | $79.15 | 2019 | |
| Amarin Pharma, INC. | $58.16 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $45.25 | 2021-2022 | |
| Hikma Pharmaceuticals USA | $39.96 | 2021 | |
| Activ Surgical, INC. | $28.53 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $27.58 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $27.54 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $27.51 | 2019 | |
| Horizon Therapeutics Plc | $26.00 | 2023 | |
| Depuy Synthes Sales INC. | $25.87 | 2019-2022 | |
| Medexus Pharma, INC. | $25.47 | 2019 | |
| Sobi, INC | $22.29 | 2019 | |
| Biocomposites INC | $18.66 | 2019 | |
| Fidia Pharma USA INC. | $13.31 | 2019 | |
| Ferring Pharmaceuticals INC. | $13.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Sullivan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.